CoChat
Sign Up
Cited by 253Peroxisome Proliferator-Activated ReceptorsParaoxonase enzyme and polymorphismsCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

Open access
Tenenbaum, Alexander, Motro, Michael, Fisman, Enrique Z·2005·Cardiovascular Diabetology
DOI 10.1186/1475-2840-4-14PMC PMC1236941
Open this paper in CoChat — free accountOpen PDF

Abstract

There are three peroxisome proliferator-activated receptors (PPARs) subtypes which are commonly designated PPAR alpha, PPAR gamma and PPAR beta/delta. PPAR alpha activation increases high density lipoprotein (HDL) cholesterol synthesis, stimulates "reverse" cholesterol transport and reduces triglycerides. PPAR gamma activation results in insulin sensitization and antidiabetic action. Until recently, the biological role of PPAR beta/delta remained unclear. However, treatment of obese animals by specific PPAR delta agonists results in normalization of metabolic parameters and reduction of adiposity. Combined treatments with PPAR gamma and alpha agonists may potentially improve insulin resistance and alleviate atherogenic dyslipidemia, whereas PPAR delta properties may prevent the development of overweight which typically accompanies "pure" PPAR gamma ligands. The new generation of dual-action PPARs – the glitazars, which target PPAR-gamma and PPAR-alpha (like muraglitazar and tesaglitazar) are on deck in late-stage clinical trials and may be effective in reducing cardiovascular risk, but their long-term clinical effects are still unknown. A number of glitazars have presented problems at a late stage of clinical trials because of serious side-effects (including ragaglitazar and farglitazar). The old and well known lipid-lowering fibric acid derivative bezafibrate is the first clinically tested pan – (alpha, beta/delta, gamma) PPAR activator. It is the only pan-PPAR activator with more than a quarter of a century of therapeutic experience with a good safety profile. Therefore, bezafibrate could be considered (indeed, as a "post hoc" understanding) as an "archetype" of a clinically tested pan-PPAR ligand. Bezafibrate leads to considerable raising of HDL cholesterol and reduces triglycerides, improves insulin sensitivity and reduces blood glucose level, significantly lowering the incidence of cardiovascular events and new diabetes in patients with features of metabolic syndrome. Clinical evidences obtained from bezafibrate-based studies strongly support the concept of pan-PPAR therapeutic approach to conditions which comprise the metabolic syndrome. However, from a biochemical point of view, bezafibrate is a PPAR ligand with a relatively low potency. More powerful new compounds with pan-PPAR activity and proven long-term safety should be highly effective in a clinical setting of patients with coexisting relevant lipid and glucose metabolism disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1475-2840-4-14

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Research works printed but not linked: 1

  1. Goldfarb B: PPAR benefits beyond glucose control. Cardiovascular effects may be even greater with next generation. DOC News. 2005, 2: 14.

Cited by

Sorted by citations

Items 201–253 of 253

Related

See all

Metadata

Authors
Tenenbaum, A., Motro, M., & Fisman, E. Z.
Affiliations
  • Sheba Medical Center (IL)
  • Tel Aviv University (IL)
Corresponding author
Tenenbaum, Alexander
ORCID
Venue
Cardiovascular Diabetology
Publisher
Springer Science and Business Media LLC
Published
2005-09-16
Volume
4
Issue
1
Pages
14-14
ISSN
1475-2840 (ISSN-L)
DOI
10.1186/1475-2840-4-14
PMC
PMC1236941
OpenAlex
W2137116210
Cited by
246
References
44
Citations by year
2026: 3 · 2025: 7 · 2024: 6 · 2023: 9 · 2022: 12 · 2021: 12 · 2020: 12 · 2019: 8 · 2018: 5 · 2017: 7 · 2016: 7 · 2015: 12 · 2014: 9 · 2013: 11 · 2012: 24
FWCI
1.64
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
bezafibrate, peroxisome proliferator-activated receptors, PPARα, PPARγ, PPARδ, metabolic syndrome, HDL cholesterol, triglycerides, insulin sensitivity, cardiovascular risk, fibrates, drug safety
MeSH terms
Hypolipidemic Agents, Bezafibrate, Cardiovascular Diseases, Coronary Disease, Diabetes Mellitus, Type 2, Humans, Hyperlipidemias, Cholesterol, HDL, Male, Middle Aged, Myocardial Infarction, Triglycerides, Peroxisome Proliferator-Activated Receptors, PPAR alpha, PPAR delta, PPAR gamma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review